Search Results 631-640 of 17694 for protein intake optimization

  1. Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... requirement) (obtained =< 14 days prior to registration) - ... - Urine protein/creatinine (UPC) ratio < 1.0 at ...

  2. Study Of ALXN1920 In Adult Participants With Primary Membranous Nephropathy (PMN) - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later phase (phase 3) ... protein creatinine ratio (UPCR). Participation eligibility. Participant ...

  3. Ph 1b Study to Evaluate GSK2110183 in Combination with Bortezomib and Dexamethasone in Subjects with Multiple Myeloma - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Capable of giving written informed consent, which includes compliance with the requirements and restrictions ...

  4. Neurosurgery - Clinical trials

    ... protein CMVpp65. Cohort 1 includes blood ... Optimal Immunotargeting of MUC1 for Advanced Pancreatic Cancer” (Principal Investigator Dr. ... Students · Admissions ...

  5. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Serum M-protein ≥ 1 g/dL;; Urine M-protein ≥ 200 ... Transfusions and growth factors must not be used to meet ...

  6. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaped/Refractory Multiple Myeloma - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... myeloma). 4. Measurable disease defined as at least one of the following: 1. Serum M-protein ≥0.5 g/dL

  7. Clinical trials - Oncology (Medical)

    In general terms, scientists will study the cells, DNA, RNA, and proteins found in the tumor tissue and/or the blood to understand more about cancer and the ...

  8. A Study of Lenvatinib for Treating Patients with Metastatic or Advanced Pheochromocytoma or Paraganglioma that Cannot be Removed by Surgery - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Urine protein/creatinine ratio ≤ 1 OR 24-hour urine protein < 1.5 gram ... requirements; Receiving ...

  9. A Study of Vaccine Therapy in Treating Patients With Recurrent Glioblastoma - Mayo Clinic

    ... optimal dosages and risks/benefits. In the later ... Vaccines made from a person's white blood cells mixed with tumor proteins ... requirements. History ...

  10. Overview - Spatial Hybrid Core - Mayo Clinic Research Core Facilities

    Through spatial multi-omic platforms, RNA and protein detection can be ... Project request intake form. More about research at Mayo Clinic. Research ...